Perceptions of pregnant women regarding antidepressant and anxiolytic medication use during pregnancy

Abstract

Objective:

The objective of this study was to explore attitudes and decision-making by pregnant women regarding antidepressant and anxiolytic use during pregnancy.

Method:

An observational study at an outer metropolitan hospital in Brisbane, Queensland. Pregnant women presenting for their first antenatal clinic visit were invited to complete a questionnaire. Participants were asked about current or previous antidepressant/anxiolytic use, influences on drug decision-making and the adequacy of information received. Perceptions were measured on a 7-point Likert scale.

Results:

A total of 503 pregnant women were surveyed. The background prevalence of anxiety and depression was 30.0% (151), with 9.3% (47) respondents using antidepressant or anxiolytic medications during the current pregnancy. Of these 47 women, 68% ceased these medications during or while trying to become pregnant, most commonly due to potential side effects to the baby (16), health professional advice (8) and symptomatology that was under control (7). While the effect was modest, decision-making was most strongly influenced by general practitioners, family and the internet.

Conclusions:

Most women cease antidepressant/anxiolytic medication before and during pregnancy for reasons other than stability of condition. This study reveals an unmet need for accessible reliable information to guide pregnant women and their care providers.

Keywords

pregnancy anti-depressants anxiolytics perceptions

Get full access to this article

View all access options for this article.

References

Slade

Johnston

Oakley Browne

et al . National Survey of Mental Health and Wellbeing: methods and key findings. Aust N Z J Psychiatry 2007; 43: 594–605.

Bennett

Einarson

Taddio

et al . Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698–709.

Andrade

Raebel

Brown

et al . Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198: 194. e1–e5.

Arroll

Macgillivray

Ogston

et al . Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005; 3: 449–456.

Sugarman

Loree

Baltes

et al . The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. PloS one 2014; 9: e106337.

Hedges

Brown

Shwalb

et al . The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 2007; 21: 102–111.

Brawman-Mintzer

Knapp

Rynn

et al . Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 874–881.

Mabbot

Robinson

Segrave

et al . Drug Utilisation Sub-Committee. Australian Statistics on Medicines http://www.pbs.gov.au/info/statistics/asm/asm-2010 (2010, accessed 20 January 2014).

Bonari

Pinto

Ahn

et al . Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49: 726–735.

10.

Grote

Bridge

Gavin

et al . A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010; 67: 1012–1024.

11.

Epstein

Moore

Bobo

WV.

Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges. Drug Healthc Patient Saf 2014; 6: 109.

12.

Cohen

Altshuler

Harlow

et al . Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499–507.

13.

Jensen

GrØn

Lidegaard

et al . Maternal depression, antidepressant use in pregnancy and Apgar scores in infants. Br J Psychiatry 2013; 202: 347–351.

14.

Moses-Kolko

Bogen

Perel

et al . Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 2372–2383.

15.

Byatt

Deligiannidis

Freeman

MP.

Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 2013; 127: 94–114.

16.

Grigoriadis

Vonder Porten

Mamisashvili

et al . Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. Br Med J 2014; 348: f6932.

17.

Salisbury

O’Grady

Battle

et al . The roles of maternal depression, serotonin reuptake inhibitor treatment, and concomitant benzodiazepine use on infant neurobehavioral functioning over the first postnatal month. Am J Psychiatry 2015; 173: 147–157.

18.

Einarson

Choi

Einarson

et al . Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009; 54: 242–246.

19.

Colvin

Slack-Smith

Stanley

et al . Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res Clin Mol Teratol 2011; 91: 142–152.

20.

Nordeng

van Gelder

Spigset

et al . Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32: 186–194.

21.

Malm

Sourander

Gissler

et al . Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data. Am J Psychiatry 2015; 172: 1224–1232.

22.

Myles

Newall

Ward

et al . Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry 2013; 47: 1002–1012.

23.

Norman

Likert scales, levels of measurement and the “laws” of statistics. Adv Health Sci Educ Theory Pract 2010; 15: 625–632.